A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): a structured summary of a study protocol for a randomised controlled trial / Jonathan Rilinger, Winfried V. Kern, Daniel Duerschmied, Alexander Supady, Christoph Bode, Dawid L. Staudacher and Tobias Wengenmayer
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
London: Springer Nature ; 2020 Freiburg: Albert-Ludwigs-Universität Freiburg ; 2020 |
| Enthalten in: |
Trials - 21, 1 (2020), 470 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rilinger, Jonathan, 1987- [VerfasserIn] |
|---|
| Links: |
nbn-resolving.de [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| Umfang: |
1 Online-Ressource (3 Seiten) ; Supplementary information (68 Seiten) |
|---|
| doi: |
10.1186/s13063-020-04447-3 |
|---|---|
| Weitere IDs: |
urn:nbn:de:bsz:25-freidok-1663100 FRUB-opus-166310 |
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1729199739 |
|---|
| LEADER | 01000cam a2200265 4500 | ||
|---|---|---|---|
| 001 | 1729199739 | ||
| 003 | DE-627 | ||
| 005 | 20230426165519.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200909s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a urn:nbn:de:bsz:25-freidok-1663100 |2 urn | |
| 024 | 7 | |a 10.1186/s13063-020-04447-3 |2 doi | |
| 024 | 8 | |a FRUB-opus-166310 |q Opus Nr. | |
| 035 | |a (DE-627)1729199739 | ||
| 035 | |a (DE-599)KXP1729199739 | ||
| 035 | |a (OCoLC)1196294840 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-101 |
| 100 | 1 | |a Rilinger, Jonathan |d 1987- |e verfasserin |0 (DE-588)1101389443 |0 (DE-627)859713687 |0 (DE-576)46988827X |4 aut | |
| 245 | 1 | 2 | |a A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): a structured summary of a study protocol for a randomised controlled trial |c Jonathan Rilinger, Winfried V. Kern, Daniel Duerschmied, Alexander Supady, Christoph Bode, Dawid L. Staudacher and Tobias Wengenmayer |
| 264 | 1 | |a London |b Springer Nature |c 2020 | |
| 264 | 2 | |a Freiburg |b Albert-Ludwigs-Universität Freiburg |c 2020 | |
| 300 | |a 1 Online-Ressource (3 Seiten) |e Supplementary information (68 Seiten) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 650 | 0 | 7 | |0 (DE-588)1206347392 |0 (DE-627)1692339907 |a COVID-19 |2 gnd |
| 650 | 0 | 7 | |0 (DE-588)4202997-1 |0 (DE-627)105154202 |0 (DE-576)210152230 |a Kontrollierte klinische Studie |2 gnd |
| 650 | 0 | 7 | |0 (DE-588)4343364-9 |0 (DE-627)153777761 |0 (DE-576)21144183X |a Protokoll |g Datenverarbeitungssystem |2 gnd |
| 650 | 0 | 7 | |0 (DE-588)4014975-4 |0 (DE-627)104653876 |0 (DE-576)208910042 |a Entzündung |2 gnd |
| 650 | 0 | 7 | |0 (DE-588)4036659-5 |0 (DE-627)106241451 |0 (DE-576)209019700 |a Lungenentzündung |2 gnd |
| 650 | 0 | 7 | |0 (DE-588)1206288906 |0 (DE-627)1692280163 |a SARS-CoV-2 |2 gnd |
| 700 | 1 | |a Kern, Winfried V. |d 1955- |e verfasserin |0 (DE-588)1105783758 |0 (DE-627)862869285 |0 (DE-576)473817608 |4 aut | |
| 700 | 1 | |a Dürschmied, Daniel Frank |d 1976- |e verfasserin |0 (DE-588)129152196 |0 (DE-627)390022462 |0 (DE-576)187844623 |4 aut | |
| 700 | 1 | |a Supady, Alexander |d 1981- |e verfasserin |0 (DE-588)139700897 |0 (DE-627)612710246 |0 (DE-576)312800924 |4 aut | |
| 700 | 1 | |a Bode, Christoph |e verfasserin |0 (DE-588)137596677 |0 (DE-627)594485282 |0 (DE-576)304489611 |4 aut | |
| 700 | 1 | |a Staudacher, Dawid |e verfasserin |0 (DE-588)102757937X |0 (DE-627)729428036 |0 (DE-576)373415451 |4 aut | |
| 700 | 1 | |a Wengenmayer, Tobias |d 1977- |e verfasserin |0 (DE-588)129286907 |0 (DE-627)707201063 |0 (DE-576)29757972X |4 aut | |
| 773 | 0 | 8 | |i Sonderdruck aus |t Trials |g 21, 1 (2020), 470 |x 1745-6215 |
| 856 | 4 | 0 | |u https://nbn-resolving.de/urn:nbn:de:bsz:25-freidok-1663100 |q application/pdf |x Resolving-System |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s13063-020-04447-3 |x Resolving-System |z kostenfrei |
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a ISIL_DE-LFER | ||
| 935 | |c so | ||
| 951 | |a BO | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3748099835 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |k Elektronischer Volltext - Zugang über WWW |y l01 |z 09-09-20 | ||
| 980 | |2 2403 |1 01 |x DE-LFER |b 3779011557 |c 00 |f --%%-- |d --%%-- |e n |j --%%-- |y l01 |z 12-10-20 | ||
| 981 | |2 2003 |1 01 |x DE-25 |r http://nbn-resolving.de/urn:nbn:de:bsz:25-freidok-1663100 | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://doi.org/10.1186/s13063-020-04447-3 | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://nbn-resolving.de/urn:nbn:de:bsz:25-freidok-1663100 | ||
| 982 | |2 2003 |1 01 |x DE-25 |8 00 |s s |a Randomised controlled trial | ||
| 982 | |2 2003 |1 01 |x DE-25 |8 01 |s s |a Tocilizumab | ||
| 982 | |2 2003 |1 01 |x DE-25 |8 02 |s s |a IL-6-Rezeptor blockade | ||
| 982 | |2 2003 |1 01 |x DE-25 |8 03 |s s |a Ventilator free days | ||